Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Company Information
About this company
Key people
Joseph E. Payne
President, Chief Executive Officer, Director
Joe Roberts
Interim Principal Financial Officer and Interim Principal Accounting Officer
Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Lance Kurata
Chief Legal Officer
James F. Barlow
Independent Director
Edward W. Holmes
Independent Director
Jing L. Marantz
Independent Director
John H. Markels
Independent Director
Magda Marquet
Independent Director
Click to see more
Key facts
- Shares in issue28.41m
- EPICARCT
- ISINUS03969T1097
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$211.96m
- Employees174
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.